(Q63577924)

English

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (English)

0 references

0 references

0 references

United States of America

0 references

start time

4 March 2019

0 references

end time

May 2019

0 references

number of participants

40

0 references

research intervention

(5E)-5-[(3aS,5R,6aS)-5-Hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]hexahydro-2(1H)-pentalenylidene]pentanoic acid

0 references

clinical trial phase

phase II clinical trial

0 references

research site

University of Michigan

0 references

Columbia University Irving Medical Center

0 references

Cleveland Clinic

0 references

Virginia Mason Medical Center

0 references

minimum age

18 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT03867097

0 references

(Q63577924)

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)